Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + fluzoparib in metastatic castration-resistant prostate cancer
ChiCTR2000035134Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospita
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of camrelizumab, Rivoceranib and fluzoparib, sponsored by Chinese PLA General Hospita. Started Jul 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranibfluzoparib
Beyond the preview
Go deeper on ChiCTR2000035134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035134.